vs
Amphastar Pharmaceuticals, Inc.（AMPH）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Amphastar Pharmaceuticals, Inc.的2.0倍（$359.3M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -2.5%，领先15.9%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.7% vs -1.8%），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（12.4% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
AMPH vs PCOR — 直观对比
营收规模更大
PCOR
是对方的2.0倍
$183.1M
营收增速更快
PCOR
高出17.5%
-1.8%
净利率更高
AMPH
高出15.9%
-2.5%
两年增速更快
PCOR
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $359.3M |
| 净利润 | $24.4M | $-9.1M |
| 毛利率 | 46.8% | 80.1% |
| 营业利润率 | 19.4% | 15.5% |
| 净利率 | 13.3% | -2.5% |
| 营收同比 | -1.8% | 15.7% |
| 净利润同比 | -35.7% | 72.4% |
| 每股收益（稀释后） | $0.51 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPCOR
| Q1 26 | — | $359.3M | ||
| Q4 25 | $183.1M | $349.1M | ||
| Q3 25 | $191.8M | $338.9M | ||
| Q2 25 | $174.4M | $323.9M | ||
| Q1 25 | $170.5M | $310.6M | ||
| Q4 24 | $186.5M | $302.0M | ||
| Q3 24 | $191.2M | $295.9M | ||
| Q2 24 | $182.4M | $284.3M |
净利润AMPHPCOR
| Q1 26 | — | $-9.1M | ||
| Q4 25 | $24.4M | $-37.6M | ||
| Q3 25 | $17.4M | $-9.1M | ||
| Q2 25 | $31.0M | $-21.1M | ||
| Q1 25 | $25.3M | $-33.0M | ||
| Q4 24 | $38.0M | $-62.3M | ||
| Q3 24 | $40.4M | $-26.4M | ||
| Q2 24 | $37.9M | $-6.3M |
毛利率AMPHPCOR
| Q1 26 | — | 80.1% | ||
| Q4 25 | 46.8% | 80.1% | ||
| Q3 25 | 51.4% | 79.7% | ||
| Q2 25 | 49.6% | 79.1% | ||
| Q1 25 | 50.0% | 79.1% | ||
| Q4 24 | 46.5% | 81.2% | ||
| Q3 24 | 53.3% | 81.4% | ||
| Q2 24 | 52.2% | 83.1% |
营业利润率AMPHPCOR
| Q1 26 | — | 15.5% | ||
| Q4 25 | 19.4% | -12.3% | ||
| Q3 25 | 13.2% | -4.4% | ||
| Q2 25 | 24.2% | -9.3% | ||
| Q1 25 | 21.9% | -11.7% | ||
| Q4 24 | 24.2% | -21.9% | ||
| Q3 24 | 29.8% | -12.3% | ||
| Q2 24 | 30.3% | -5.2% |
净利率AMPHPCOR
| Q1 26 | — | -2.5% | ||
| Q4 25 | 13.3% | -10.8% | ||
| Q3 25 | 9.0% | -2.7% | ||
| Q2 25 | 17.8% | -6.5% | ||
| Q1 25 | 14.8% | -10.6% | ||
| Q4 24 | 20.4% | -20.6% | ||
| Q3 24 | 21.1% | -8.9% | ||
| Q2 24 | 20.8% | -2.2% |
每股收益（稀释后）AMPHPCOR
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.51 | $-0.25 | ||
| Q3 25 | $0.37 | $-0.06 | ||
| Q2 25 | $0.64 | $-0.14 | ||
| Q1 25 | $0.51 | $-0.22 | ||
| Q4 24 | $0.74 | $-0.42 | ||
| Q3 24 | $0.78 | $-0.18 | ||
| Q2 24 | $0.73 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $386.0M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $1.2B |
| 总资产 | $1.6B | $2.1B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHPCOR
| Q1 26 | — | $386.0M | ||
| Q4 25 | $282.8M | $768.5M | ||
| Q3 25 | $276.2M | $684.0M | ||
| Q2 25 | $231.8M | $620.9M | ||
| Q1 25 | $236.9M | $566.7M | ||
| Q4 24 | $221.6M | $775.4M | ||
| Q3 24 | $250.5M | $756.9M | ||
| Q2 24 | $217.8M | $735.4M |
总债务AMPHPCOR
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHPCOR
| Q1 26 | — | $1.2B | ||
| Q4 25 | $788.8M | $1.3B | ||
| Q3 25 | $776.7M | $1.2B | ||
| Q2 25 | $757.5M | $1.2B | ||
| Q1 25 | $751.3M | $1.2B | ||
| Q4 24 | $732.3M | $1.3B | ||
| Q3 24 | $727.7M | $1.3B | ||
| Q2 24 | $713.3M | $1.3B |
总资产AMPHPCOR
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.6B | $2.2B | ||
| Q3 25 | $1.7B | $2.1B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.5B | $2.0B |
负债/权益比AMPHPCOR
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $76.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHPCOR
| Q1 26 | — | $76.8M | ||
| Q4 25 | $32.9M | $114.9M | ||
| Q3 25 | $52.6M | $88.5M | ||
| Q2 25 | $35.6M | $30.8M | ||
| Q1 25 | $35.1M | $66.0M | ||
| Q4 24 | $29.0M | $29.1M | ||
| Q3 24 | $60.0M | $39.3M | ||
| Q2 24 | $69.1M | $58.7M |
自由现金流AMPHPCOR
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $109.2M | ||
| Q3 25 | $47.2M | $83.1M | ||
| Q2 25 | $25.0M | $27.9M | ||
| Q1 25 | $24.4M | $62.0M | ||
| Q4 24 | $16.6M | $17.4M | ||
| Q3 24 | $46.2M | $35.7M | ||
| Q2 24 | $63.1M | $56.8M |
自由现金流率AMPHPCOR
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 31.3% | ||
| Q3 25 | 24.6% | 24.5% | ||
| Q2 25 | 14.3% | 8.6% | ||
| Q1 25 | 14.3% | 20.0% | ||
| Q4 24 | 8.9% | 5.8% | ||
| Q3 24 | 24.1% | 12.1% | ||
| Q2 24 | 34.6% | 20.0% |
资本支出强度AMPHPCOR
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 1.6% | ||
| Q3 25 | 2.8% | 1.6% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 1.3% | ||
| Q4 24 | 6.7% | 3.9% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 3.3% | 0.7% |
现金转化率AMPHPCOR
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PCOR
暂无分部数据
